Lexeo Therapeutics, Inc. (LXEO)

NASDAQ: LXEO · Real-Time Price · USD

5.02

+0.05 (1.01%)

At close: Sep 5, 2025, 4:00 PM

5.02

0.00 (0.00%)

After-hours: Sep 5, 2025, 5:34 PM EDT

Lexeo Therapeutics Employees

Lexeo Therapeutics had 72 employees as of December 31, 2024. The number of employees increased by 14 or 24.14% compared to the previous year.

Employees

72

Change (1Y)

14

Growth (1Y)

24.14%

Revenue / Employee

n/a

Profits / Employee

-$1,585,722

Market Cap

271.07M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	72	14	24.14%
Dec 31, 2023	58	34	141.67%
Dec 31, 2021	24	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

LXEO News

22 days ago - Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
2 months ago - Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewsWire
2 months ago - Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics - GlobeNewsWire
3 months ago - Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases - GlobeNewsWire
4 months ago - Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
4 months ago - Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement - Seeking Alpha
4 months ago - Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - GlobeNewsWire
5 months ago - Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials - Benzinga